IJSTR

International Journal of Scientific & Technology Research

IJSTR@Facebook IJSTR@Twitter IJSTR@Linkedin
Home About Us Scope Editorial Board Blog/Latest News Contact Us
CALL FOR PAPERS
AUTHORS
DOWNLOADS
CONTACT
QR CODE
IJSTR-QR Code

IJSTR >> Volume 3- Issue 6, June 2014 Edition



International Journal of Scientific & Technology Research  
International Journal of Scientific & Technology Research

Website: http://www.ijstr.org

ISSN 2277-8616



Allele Frequency Of P53 Gene Arg72Pro In Sudanese Meningioma Patients And Controls

[Full Text]

 

AUTHOR(S)

Alsadig Gassoum, Mohamed A.Arbab, Sawsan A. H. Aldeaf, Lamya A. Elhassan, Elshibli Elshibli, Ahmed M. Elhassan,

 

KEYWORDS

Key words: meningioma, P53 gene,

 

ABSTRACT

Abstract: The Meningiomas are one of the commonest intracranial tumors and account for 20% of all primary intracranial neoplasms. However, the true incidence is likely to be much higher, since many benign meningiomas do not produce symptoms. In autopsy studies, 2.3% of individuals harbored undiagnosed asymptomatic meningiomas, suggesting that such tumors are up to 1000 times more common than their clinically detected counterparts. Material and Method: This is a cross-sectional study that had been performed at the National Center for Neurological Sciences during February 2011 to December 2013. Result: Molecular screening of the 180 meningioma specimens, showed that the most common allele of p53 gene codon 72, in meningioma , was the arginine variant (Arg/arg), in 157 (87.2%) of the cases.

 

REFERENCES

[1]. Louis, D. N., et al. "The 2007 WHO classification of tumours of the central nervous system." Acta Neuropathol. 114.2 (2007): 97-109.

[2]. Harrison, M. J., et al. "Radiation-induced meningiomas: experience at the Mount Sinai Hospital and review of the literature." J.Neurosurg. 75.4 (1991): 564-74.

[3]. Nakasu, S., A. Hirano, and T. Shimura. "[Incidental meningioma. Autopsy study]." Neurol.Med.Chir (Tokyo) 25.11 (1985): 928-32.

[4]. Abu-Salih, H. S. and A. M. Abdul-Rahman. "Tumors of the brain in the Sudan." Surg.Neurol. 29.3 (1988): 194-96.

[5]. Jellinger, K. A. "Meningiomas. A Comprehensive Text." Eur.J.Neurol. (2010).

[6]. Langford, L. A., C. S. Cooksley, and F. DeMonte. "Comparison of MIB-1 (Ki-67) antigen and bromodeoxyuridine proliferation indices in meningiomas." Hum.Pathol. 27.4 (1996): 350-54.

[7]. Schneider-Stock, R., et al. "Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer." Am.J.Pathol. 164.4 (2004): 1233-41.

[8]. Bellini, I., et al. "DeltaN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region." Hum.Mutat. 31.4 (2010): 456-65.

[9]. Kawajiri, K., et al. "Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer." Carcinogenesis 14.6 (1993): 1085-89.

[10]. Matakidou, A., T. Eisen, and R. S. Houlston. "TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis." Mutagenesis 18.4 (2003):

[11]. Amatya, V. J., Y. Takeshima, and K. Inai. "Methylation of p14(ARF) gene in meningiomas and its correlation to the p53 expression and mutation." Mod.Pathol. Wiemels J, Wrensch M and Claus EB.Epidemiology and etiology of meningioma J Neurooncol. 2010; 99:307-14

[12]. Bondy M and Ligon BL. Epidemiology and etiology of intracranial meningioma: a review. J Neurooncol. 1996; 29:197-205

[13]. Amirjamshidi A, Mehrazin M and Abbassion K. Meningiomas of the central nervous system occurring below the age of 17: report of 24 cases not associated with neurofibromatosis and review of literature 97. Childs Nerv Syst. 2000; 16:406-16

[14]. Whibley, C., P. D. Pharoah, and M. Hollstein. "p53 polymorphisms: cancer implications." Nat.Rev.Cancer 9.2 (2009): 95-107.

[15]. Ruttledge, M. H., et al. "Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease." Am.J.Hum.Genet. 59.2 (1996): 331-42.

[16]. Phelan, C. M., et al. "Chromosome 17 abnormalities and lack of TP53 mutations in paediatric central nervous system tumours." Hum.Genet. 96.6 (1995): 684-90.

[17]. Bereir R.E.H., Mohamed1 H.S., Seielstad M, El Hassan A.M., Khalil1 E.A.G., Peacock C.S., Blackwell J.M & Ibrahim M.E.(2003). Allele frequency and genotype distribution of polymorphisms within disease-related genes is influenced by ethnic population sub-structuring in Sudan. Genetica 119:57-63.

[18]. Eltahir, H. A., et al. "p53 Codon 72 arginine/proline polymorphism and cancer in Sudan." Mol.Biol.Rep. 39.12 (2012): 10833-36.

[19]. Eltahir, H. A., A. M. Elhassan, and M. E. Ibrahim. "Contribution of retinoblastoma LOH and the p53 Arg/Pro polymorphism to cervical cancer." Mol.Med.Rep. 6.3 (2012): 473-76.

[20]. Osman, E. A., et al. "Frequencies of BCR-ABL1 fusion transcripts among Sudanese chronic myeloid leukaemia patients." Genet.Mol.Biol. 33.2 (2010): 229-31.

[21]. Sand, L., et al. "p53 Codon 72 polymorphism in oral exfoliated cells in a Sudanese population." In Vivo 26.1 (2012): 59-62.

[22]. Hou, J., et al. "p53 codon 72 polymorphism and breast cancer risk: A meta-analysis." Exp.Ther.Med. 5.5 (2013): 1397-402.

[23]. Akkiprik, M., et al. "Analysis of p53 gene polymorphisms and protein over-expression in patients with breast cancer." Pathol.Oncol.Res. 15.3 (2009): 359-68.

[24]. Bonafe, M., et al. "Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients." Clin.Cancer Res. 9.13 (2003): 4860-64.

[25]. Xu, Y., et al. "p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer." Clin.Cancer Res. 11.20 (2005): 7328-33.

[26]. Tang, W., et al. "Association of p53 Arg72Pro polymorphism with gastric cancer: a meta-analysis." Biomarkers 17.7 (2012): 597-603.

[27]. Almeida, L. O., et al. "Polymorphisms and DNA methylation of gene TP53 associated with extra-axial brain tumors." Genet.Mol.Res. 8.1 (2009): 8-18.

[28]. Pezeshki, A., et al. "p53 codon 72 polymorphism in basal cell carcinoma of the skin." Pathol.Oncol.Res. 12.1 (2006): 29-33.

[29]. Malmer, B., et al. "p53 Genotypes and risk of glioma and meningioma." Cancer Epidemiol.Biomarkers Prev. 14.9 (2005): 2220-23.

[30]. Bansal, A., et al. "Implication of DNA repair genes in prostate tumourigenesis in Indian males." Indian J.Med.Res. 136.4 (2012): 622-32.

[31]. Engin, A. B., et al. "Association between XRCC1 ARG399GLN and P53 ARG72PRO polymorphisms and the risk of gastric and colorectal cancer in Turkish population." Arh.Hig.Rada Toksikol. 62.3 (2011): 207-14.

[32]. Cho, H., et al. "Role of p53 gene mutation in tumor aggressiveness of intracranial meningiomas." J.Korean Med.Sci. 14.2 (1999): 199-205.

[33]. Alsadig Gassoum,2,5 Mohamed A. Arbab1,2, Sawsan A.H. Aldeaf,2 Lamyaa A. Elhassan,4,Elshibli Elshibli6 Ahmed M. Elhassan3